Payment overview · 2025
General Payments
$115.07
5 reported records · 2 companies
Healthcare provider profile · identity verified
Gor Agababian, M.D.
Allopathic & Osteopathic Physicians|General Practice · GLENDALE, CA · NPI 1063442143
Verified facts
What the public records show
CMS Open Payments records show Gor Agababian, M.D. received $115.07 in general payments during 2025 across 5 reported records.
ABBVIE INC. accounted for 65.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Linzess.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Linzess by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $75.52 | 65.6% | 3 | 2025 |
| CooperSurgical, Inc. | Unresolved — no canonical attribution shown | $39.55 | 34.4% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $115.07 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CREON Normalized: creon |
Drug | ABBVIE INC. | $75.52 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $75.52 | 3 | 2025 |
Source payment records
|
|||||
| Paragard T 380A Normalized: paragard t 380a |
Drug | CooperSurgical, Inc. | $39.55 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 64 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 61 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
64 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
61 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 351 | 62 |
| Amlodipine Besylate | Amlodipine Besylate | 322 | 52 |
| Clonidine Hcl | Clonidine Hcl | 302 | 42 |
| Donepezil Hcl | Donepezil Hcl | 251 | 38 |
| Metformin Hcl | Metformin Hcl | 248 | 38 |
| Vascepa | Icosapent Ethyl | 245 | 38 |
| Ibuprofen | Ibuprofen | 224 | 38 |
| Omeprazole | Omeprazole | 190 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 175 | 23 |
| Icosapent Ethyl | Icosapent Ethyl | 163 | 38 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 161 | 22 |
| Furosemide | Furosemide | 136 | 18 |
| Benazepril Hcl | Benazepril Hcl | 131 | 18 |
| Meclizine Hcl | Meclizine Hcl | 129 | 16 |
| Alendronate Sodium | Alendronate Sodium | 114 | 15 |
| Potassium Chloride | Potassium Chloride | 113 | 14 |
| Losartan Potassium | Losartan Potassium | 108 | 20 |
| Simvastatin | Simvastatin | 98 | 19 |
| Levothyroxine Sodium | Levothyroxine Sodium | 89 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 89 | 11 |
| Tamsulosin Hcl | Tamsulosin Hcl | 89 | 16 |
| Meloxicam | Meloxicam | 85 | 19 |
| Gabapentin | Gabapentin | 82 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 79 | 17 |
| Lisinopril | Lisinopril | 77 | 17 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 73 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 71 | 13 |
| Pantoprazole Sodium | Pantoprazole Sodium | 71 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 68 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 66 | suppressed |
| Creon | Lipase/Protease/Amylase | 64 | 11 |
| Linzess | Linaclotide | 61 | suppressed |
| Nitroglycerin | Nitroglycerin | 59 | suppressed |
| Celecoxib | Celecoxib | 58 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 55 | suppressed |
| Famotidine | Famotidine | 44 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 44 | suppressed |
| Eliquis | Apixaban | 43 | suppressed |
| Naproxen | Naproxen | 39 | suppressed |
| Ranolazine Er | Ranolazine | 39 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 38 | suppressed |
| Ozempic | Semaglutide | 38 | suppressed |
| Carvedilol | Carvedilol | 37 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 34 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 33 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Atenolol | Atenolol | 31 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 31 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 31 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 31 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Ramipril | Ramipril | 28 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 27 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 26 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 25 | suppressed |
| Glimepiride | Glimepiride | 25 | suppressed |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 23 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Azithromycin | Azithromycin | 22 | 17 |
| Glyburide | Glyburide | 21 | suppressed |
| Jardiance | Empagliflozin | 21 | suppressed |
| Clonidine | Clonidine | 20 | suppressed |
| Colchicine | Colchicine | 20 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 20 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 17 |
| Clotrimazole | Clotrimazole | 18 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 16 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Nateglinide | Nateglinide | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Silodosin | Silodosin | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Allopurinol | Allopurinol | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Crestor | Rosuvastatin Calcium | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Naproxen-Esomeprazole Mag | Naproxen/Esomeprazole Mag | 13 | suppressed |
| Norvasc | Amlodipine Besylate | 13 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 11 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Diflorasone Diacetate | Diflorasone Diacetate | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Meloxicam | Meloxicam, Submicronized | 12 | suppressed |
| Nexletol | Bempedoic Acid | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Klor-Con 8 | Potassium Chloride | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
| Trulance | Plecanatide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $115.07 · 5 records | ABBVIE INC. | CREON, LINZESS, Paragard T 380A | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error